RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
GlycoMimetics Stock

GlycoMimetics ROE 2024

GlycoMimetics ROE

-0.96

Ticker

GLYC

ISIN

US38000Q1022

WKN

A1W8HZ

In 2024, GlycoMimetics's return on equity (ROE) was -0.96, a -11.74% increase from the -1.09 ROE in the previous year.

GlycoMimetics Aktienanalyse

What does GlycoMimetics do?

GlycoMimetics Inc is a biopharmaceutical company specializing in the discovery and development of new drugs for the treatment of cancer and inflammatory diseases. The company was founded in 2003 and is headquartered in Rockville, Maryland. GlycoMimetics' business model is based on the application of glycomimetics, a class of molecules that mimic glycoproteins found in cells. These molecules act in various ways, offering unique therapeutic possibilities in the treatment of cancer and inflammatory diseases. The company conducts research and development in various areas, including the discovery of new drugs, preclinical and clinical drug development, and the evaluation of drug candidates for their transition into clinical trials. One of GlycoMimetics' most important developments is a drug called Rivipansel. This medication is used for the treatment of acute pain and crises in patients with sickle cell anemia. A Phase III clinical trial for Rivipansel was successfully completed in 2019. Another significant aspect of GlycoMimetics' business model is its collaboration with other companies specializing in similar technologies. For example, the company has partnered with Apollomics to advance the development of GMI-1271, a drug candidate for the treatment of Acute Myeloid Leukemia (AML). GlycoMimetics has various research and development areas that are crucial for the development and testing of drug candidates in clinical trials. The company has expertise in chemistry and biological sciences and employs researchers and scientists with diverse backgrounds. One of GlycoMimetics' divisions is medicinal chemistry, which focuses on the synthesis of natural compounds and chemical compounds to identify and develop new drug candidates. The company also has expertise in protein diagnostics, which are used to validate target molecules and assess the effectiveness of drug candidates. Another important division of GlycoMimetics is the field of immunology. Here, the company explores the role of glycoproteins in immune reactions and develops drugs for the treatment of autoimmune diseases. Overall, GlycoMimetics has strong research and development capabilities, enabling the company to develop new drug candidates, conduct clinical trials, and achieve successful growth. With its innovative developments and products, GlycoMimetics contributes to the improvement of the health of many patients and is an important player in the biopharmaceutical industry. GlycoMimetics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding GlycoMimetics's Return on Equity (ROE)

GlycoMimetics's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing GlycoMimetics's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

GlycoMimetics's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in GlycoMimetics’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about GlycoMimetics stock

What is the ROE (Return on Equity) of GlycoMimetics this year?

The ROE of GlycoMimetics this year is -0.96 undefined.

How has the Return on Equity (ROE) of GlycoMimetics developed compared to the previous year?

The ROE of GlycoMimetics has increased by -11.74% decreased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of GlycoMimetics?

A high ROE indicates that GlycoMimetics generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of GlycoMimetics?

A low ROE can indicate that GlycoMimetics is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of GlycoMimetics affect the company?

A change in ROE (Return on Equity) of GlycoMimetics can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of GlycoMimetics?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of GlycoMimetics?

Some factors that can influence GlycoMimetics's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does GlycoMimetics pay?

Over the past 12 months, GlycoMimetics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, GlycoMimetics is expected to pay a dividend of 0 USD.

What is the dividend yield of GlycoMimetics?

The current dividend yield of GlycoMimetics is .

When does GlycoMimetics pay dividends?

GlycoMimetics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of GlycoMimetics?

GlycoMimetics paid dividends every year for the past 0 years.

What is the dividend of GlycoMimetics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is GlycoMimetics located?

GlycoMimetics is assigned to the 'Health' sector.

Wann musste ich die Aktien von GlycoMimetics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of GlycoMimetics from 11/20/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/20/2024.

When did GlycoMimetics pay the last dividend?

The last dividend was paid out on 11/20/2024.

What was the dividend of GlycoMimetics in the year 2023?

In the year 2023, GlycoMimetics distributed 0 USD as dividends.

In which currency does GlycoMimetics pay out the dividend?

The dividends of GlycoMimetics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The GlycoMimetics stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von GlycoMimetics

Our stock analysis for GlycoMimetics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of GlycoMimetics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.